OPKO Health’s (OPK) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $3.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.30) EPS.

OPK has been the subject of a number of other reports. Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.80 on Wednesday. The business has a 50-day simple moving average of $1.65 and a 200 day simple moving average of $1.57. OPKO Health has a one year low of $0.92 and a one year high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -9.47 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. On average, research analysts anticipate that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock in a transaction on Friday, January 17th. The stock was acquired at an average price of $1.47 per share, with a total value of $220,500.00. Following the acquisition, the chief executive officer now directly owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This represents a 0.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders acquired 964,971 shares of company stock worth $1,493,692. Corporate insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Rubric Capital Management LP increased its holdings in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares during the period. Barclays PLC grew its position in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after purchasing an additional 329,870 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 217,450 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of OPKO Health in the third quarter worth $190,000. Finally, FMR LLC raised its position in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.